Abstract
Non-viral gene delivery is an important approach in order to establish safe in vivo gene therapy in the clinic. Although viral vectors currently exhibit superior gene transfer efficacy, the safety aspect of viral gene delivery is a concern. In order to improve non-viral in vivo gene delivery we have designed a pharmaceutical platform called Bioplex (biological complex). The concept of Bioplex is to link functional entities via hybridising anchors, such as Peptide Nucleic Acids (PNA), directly to naked DNA. In order to promote delivery functional entities consisting of biologically active peptides or carbohydrates, are linked to the PNA anchor. The PNA acts as genetic glue and hybridises with DNA in a sequence specific manner. By using functional entities, which elicit receptor-mediated endocytosis, improved endosomal escape and enhance nuclear entry we wish to improve the transfer of genetic material into the cell. An important aspect is that the functional entities should also have tissue-targeting properties in vivo. Examples of functional entities investigated to date are the Simian virus 40 nuclear localisation signal to improve nuclear uptake and different carbohydrate ligands in order to achieve receptor specific uptake. The delivery system is also endowed with regulatory capability, since the release of functional entities can be controlled. The aim is to create a safe, pharmaceutically defined and stable delivery system for nucleic acids with enhanced transfection properties that can be used in the clinic.
Keywords: non-viral vectors, peptide nucleic acid, bioplex, gene therapy, plasmids
Current Pharmaceutical Design
Title: Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Volume: 11 Issue: 28
Author(s): O. E. Simonson, M. G. Svahn, E. Tornquist, K. E. Lundin and C. I.E. Smith
Affiliation:
Keywords: non-viral vectors, peptide nucleic acid, bioplex, gene therapy, plasmids
Abstract: Non-viral gene delivery is an important approach in order to establish safe in vivo gene therapy in the clinic. Although viral vectors currently exhibit superior gene transfer efficacy, the safety aspect of viral gene delivery is a concern. In order to improve non-viral in vivo gene delivery we have designed a pharmaceutical platform called Bioplex (biological complex). The concept of Bioplex is to link functional entities via hybridising anchors, such as Peptide Nucleic Acids (PNA), directly to naked DNA. In order to promote delivery functional entities consisting of biologically active peptides or carbohydrates, are linked to the PNA anchor. The PNA acts as genetic glue and hybridises with DNA in a sequence specific manner. By using functional entities, which elicit receptor-mediated endocytosis, improved endosomal escape and enhance nuclear entry we wish to improve the transfer of genetic material into the cell. An important aspect is that the functional entities should also have tissue-targeting properties in vivo. Examples of functional entities investigated to date are the Simian virus 40 nuclear localisation signal to improve nuclear uptake and different carbohydrate ligands in order to achieve receptor specific uptake. The delivery system is also endowed with regulatory capability, since the release of functional entities can be controlled. The aim is to create a safe, pharmaceutically defined and stable delivery system for nucleic acids with enhanced transfection properties that can be used in the clinic.
Export Options
About this article
Cite this article as:
Simonson E. O., Svahn G. M., Tornquist E., Lundin E. K. and Smith I.E. C., Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids, Current Pharmaceutical Design 2005; 11 (28) . https://dx.doi.org/10.2174/138161205774580813
DOI https://dx.doi.org/10.2174/138161205774580813 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular and Humoral Responses following Minimally Invasive Surgery: Role of Reactive Oxygen Species
Current Metabolomics The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Dynamics of CD86 Expression on Allergic Inflammation - New Insights
Recent Patents on Inflammation & Allergy Drug Discovery Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
Current Pharmaceutical Design MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy A Review on Synthesis, Anticancer and Antiviral Potentials of Pyrimidine Derivatives
Current Bioactive Compounds